In addition, it has been reported in many studies that the overexpression of ERCC1 reduces the overall- and event-free survival rate in non-small cell lung cancer, head and neck cancer, gastric cancer, esophageal cancer, and breast cancer undergoing CRT [11,12,13]. The gene discussed is ERCC1; the disease is gastric cancer.